Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(7): e42660, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37644918

ABSTRACT

Cardiac papillary fibroelastomas (CPFs) are rare benign cardiac neoplasms that carry a high risk of embolization if not diagnosed and managed in a timely manner. As most patients are asymptomatic, CPF may be incidentally detected on transthoracic echocardiography (TTE) when performed for other indications. Management of incidental CPF in asymptomatic patients is debatable. We report an unusual case of an incidental CPF in an asymptomatic patient admitted to the hospital for presumed infective endocarditis (IE). Two weeks following laser resection of laryngeal cancer (LC), a new pansystolic murmur was audible during a routine cardiology visit. Outpatient TTE revealed a "vegetation-like" lesion on the mitral valve (MV). Blood cultures (BC) with Gram-positive cocci in clusters (GPC) were reported within 24 hours. This prompted hospital admission for empiric antibiotics. A transesophageal echocardiogram (TEE) confirmed the lesion to be an echogenic mass attached to the MV consistent with CPF. Repeat BC, prior to empiric antibiotic initiation, were all negative. In the absence of all other signs and symptoms of IE, it was determined that the initial BC was false positive and IE was ruled out. Surgical resection was performed due to the potential risk of embolization. The pathology confirmed the diagnosis of CPF with negative tissue cultures.

2.
Transpl Infect Dis ; 22(5): e13382, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32583620

ABSTRACT

BACKGROUND: The impact of COVID-19 on heart transplant (HTx) recipients remains unclear, particularly in the early post-transplant period. METHODS: We share novel insights from our experience in five HTx patients with COVID-19 (three within 2 months post-transplant) from our institution at the epicenter of the pandemic. RESULTS: All five exhibited moderate (requiring hospitalization, n = 3) or severe (requiring ICU and/or mechanical ventilation, n = 2) illness. Both cases with severe illness were transplanted approximately 6 weeks before presentation and acquired COVID-19 through community spread. All five patients were on immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus, and three that were transplanted within the prior 2 months were additionally on prednisone. The two cases with severe illness had profound lymphopenia with markedly elevated C-reactive protein, procalcitonin, and ferritin. All had bilateral ground-glass opacities on chest imaging. MMF was discontinued in all five, and both severe cases received convalescent plasma. All three recent transplants underwent routine endomyocardial biopsies, revealing mild (n = 1) or no acute cellular rejection (n = 2), and no visible viral particles on electron microscopy. Within 30 days of admission, the two cases with severe illness remain hospitalized but have clinically improved, while the other three have been discharged. CONCLUSIONS: COVID-19 appears to negatively impact outcomes early after heart transplantation.


Subject(s)
Allografts/pathology , COVID-19/immunology , Endocardium/pathology , Graft Rejection/pathology , Heart Transplantation/adverse effects , Myocardium/pathology , Aged , Allografts/immunology , Allografts/ultrastructure , Biopsy , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/pathology , COVID-19 Nucleic Acid Testing , Endocardium/immunology , Endocardium/ultrastructure , Female , Graft Rejection/immunology , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents/adverse effects , Male , Microscopy, Electron , Middle Aged , Myocardium/immunology , Myocardium/ultrastructure , New York City/epidemiology , Pandemics , Retrospective Studies , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Severity of Illness Index , Time Factors
4.
Clin J Am Soc Nephrol ; 13(2): 348-355, 2018 02 07.
Article in English | MEDLINE | ID: mdl-29070522

ABSTRACT

Left ventricular assist devices (LVADs) are common and implantation carries risk of AKI. LVADs are used as a bridge to heart transplantation or as destination therapy. Patients with refractory heart failure that develop chronic cardiorenal syndrome and CKD often improve after LVAD placement. Nevertheless, reversibility of CKD is hard to predict. After LVAD placement, significant GFR increases may be followed by a late return to near baseline GFR levels, and in some patients, a decline in GFR. In this review, we discuss changes in GFR after LVAD placement, the incidence of AKI and associated mortality after LVAD placement, the management of AKI requiring RRT, and lastly, we review salient features about cardiorenal syndrome learned from the LVAD experience. In light of the growing number of patients using LVADs as a destination therapy, it is important to understand the effect of these devices on the kidney. Additional research and long-term data are required to better understand the relationship between the LVAD and the kidney.


Subject(s)
Cardio-Renal Syndrome/physiopathology , Glomerular Filtration Rate , Heart Failure/therapy , Heart-Assist Devices , Kidney/physiopathology , Renal Insufficiency, Chronic/physiopathology , Stroke Volume , Ventricular Function, Left , Acute Kidney Injury/epidemiology , Acute Kidney Injury/physiopathology , Acute Kidney Injury/therapy , Cardio-Renal Syndrome/diagnosis , Cardio-Renal Syndrome/mortality , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Heart-Assist Devices/adverse effects , Humans , Incidence , Prosthesis Design , Recovery of Function , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/mortality , Renal Replacement Therapy , Risk Assessment , Risk Factors , Treatment Outcome
5.
Artif Organs ; 40(12): E292-E304, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27911025

ABSTRACT

Transcatheter aortic valve replacement (TAVR) has emerged as a life-saving and effective alternative to surgical valve replacement in high-risk, elderly patients with severe calcific aortic stenosis. Despite its early promise, certain limitations and adverse events, such as suboptimal placement and valve migration, have been reported. In the present study, it was aimed to evaluate the effect of various TAVR deployment locations on the procedural outcome by assessing the risk for valve migration. The deployment of a balloon-expandable Edwards SAPIEN valve was simulated via finite element analysis in a patient-specific calcified aortic root, which was reconstructed from CT scans of a retrospective case of valve migration. The deployment location was parametrized in three configurations and the anchorage was quantitatively assessed based on the contact between the stent and the native valve during the deployment and recoil phases. The proximal deployment led to lower contact area between the native leaflets and the stent which poses higher risk for valve migration. The distal and midway positions resulted in comparable outcomes, with the former providing a slightly better anchorage. The approach presented might be used as a predictive tool for procedural planning in order to prevent prosthesis migration and achieve better clinical outcomes.


Subject(s)
Aorta/surgery , Aortic Valve Stenosis/surgery , Aortic Valve/pathology , Calcinosis/surgery , Prosthesis Failure , Transcatheter Aortic Valve Replacement/methods , Aged, 80 and over , Aorta/anatomy & histology , Aortic Valve/surgery , Computer Simulation , Finite Element Analysis , Humans , Male , Models, Anatomic , Models, Biological , Prosthesis Design , Retrospective Studies , Treatment Outcome
6.
Arterioscler Thromb Vasc Biol ; 23(6): 1008-13, 2003 Jun 01.
Article in English | MEDLINE | ID: mdl-12676801

ABSTRACT

OBJECTIVE: The development of intimal hyperplasia involves smooth muscle cell (SMC) migration into the intima and proliferation. Matrix metalloproteinases and their tissue inhibitors play important roles in this process. In this study, we describe a novel in vitro model for studying SMC migration through the vessel wall. METHODS AND RESULTS: Human aortic SMCs (hASMCs) labeled with 125I-iododeoxyuridine or unlabeled were grown on the stromal aspect of the human amniotic membrane. Mechanical damage to endothelial cells grown on the basement membrane and addition of growth factors or platelets were characterized for their effect on SMC migration into the stroma both by histological methods and by measuring the radioactivity associated with the membrane after removal of noninvasive SMCs. To assess the reliability of the model, the cells were infected with a recombinant adenovirus encoding the tissue inhibitor of metalloproteinase-1 (TIMP-1). Addition of a platelet-derived growth factor gradient stimulated hASMC infiltration into the stroma. This effect was abolished with TIMP-1-transduced hASMC, confirming that TIMP-1 overexpression blocks SMC invasion of the stroma. CONCLUSIONS: This in vitro model of SMC migration in the vessel wall provides an inexpensive, quantitative, and reliable tool to study the molecular and cellular mechanisms of intimal hyperplasia.


Subject(s)
Amnion , Muscle, Smooth, Vascular/cytology , Adenoviridae/genetics , Aorta/cytology , Basement Membrane , Cell Movement , Cells, Cultured/cytology , Coculture Techniques , Endothelial Cells/cytology , Endothelium, Vascular/cytology , Genetic Vectors/genetics , Humans , Matrix Metalloproteinases/physiology , Recombinant Fusion Proteins/physiology , Stress, Mechanical , Tissue Inhibitor of Metalloproteinase-1/biosynthesis , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-1/physiology , Transduction, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...